2. Academic Validation
  3. Synergistic Interactions of MmpL3 Inhibitors with Antitubercular Compounds In Vitro

Synergistic Interactions of MmpL3 Inhibitors with Antitubercular Compounds In Vitro

  • Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02399-16. doi: 10.1128/AAC.02399-16.
Wei Li 1,  Andrea Sanchez-Hidalgo 1,  Victoria Jones 1,  Vinicius Calado Nogueira de Moura 1,  E Jeffrey North 2,  Mary Jackson 3
Affiliations

Affiliations

  • 1 Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
  • 2 Creighton University, School of Pharmacy & Health Professions, Department of Pharmacy Sciences, Omaha, Nebraska, USA.
  • 3 Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA Mary.Jackson@colostate.edu.
PMID: 28115355 DOI: 10.1128/AAC.02399-16
Abstract

A number of inhibitors of the essential Mycobacterium tuberculosis mycolic acid transporter, MmpL3, are currently under development as potential novel antituberculosis agents. Using the checkerboard method to study the interaction profiles of various antituberculosis drugs or experimental compounds with two different chemotypes inhibiting this transporter (indolcarboxamides and adamantyl ureas), we showed that MmpL3 inhibitors act synergistically with rifampin, bedaquiline, clofazimine, and β-lactams.

Keywords

MmpL3; Mycobacterium; Mycobacterium tuberculosis; drug synergism; mycolic acids; tuberculosis.

Figures
Products